

1 **Title:** A novel time-based surface EMG measure for quantifying hypertonia in paretic arm muscles  
2 during daily activities after hemiparetic stroke

3 **Authors:** M. Hongchul Sohn<sup>1,\*</sup>, Jasjit Deol<sup>1,2</sup> and Julius P.A. Dewald<sup>1,3,4</sup>

4 <sup>1</sup> Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine  
5 Northwestern University, Chicago IL, USA

6 <sup>2</sup> Neuroscience and Mental Health Institute Graduate Program, University of Alberta, Edmonton  
7 AB, Canada

8 <sup>3</sup> Department of Biomedical Engineering, McCormick School of Engineering, Northwestern  
9 University, Evanston IL, USA

10 <sup>4</sup> Department of Physical Medicine and Rehabilitation, Feinberg School of Medicine,  
11 Northwestern University, Evanston IL, USA

12 \* Correspondence: [hongchul.sohn@northwestern.edu](mailto:hongchul.sohn@northwestern.edu)

13

14 **Keywords:** EMG; Stroke; Arm Motor Deficit; Remote Monitoring; Home-based Setting

15 **ABSTRACT**

16 After stroke, paretic arm muscles are constantly exposed to abnormal neural drive from the injured  
17 brain. As such, hypertonia, broadly defined as an increase in muscle tone, is prevalent especially  
18 in distal muscles, which impairs daily function or in long-term leads to a flexed resting posture in  
19 the wrist and fingers. However, there currently is no quantitative measure that can reliably track  
20 how hypertonia is expressed on daily basis. In this study, we propose a novel time-based surface  
21 electromyography (sEMG) measure that can overcome the limitations of the coarse clinical scales  
22 often measured in functionally irrelevant context and the magnitude-based sEMG measures that  
23 suffer from signal non-stationarity. We postulated that the key to robust quantification of  
24 hypertonia is to capture the “true” baseline in sEMG for each measurement session, by which we  
25 can define the relative duration of activity over a short time segment continuously tracked in a  
26 sliding window fashion. We validate that the proposed measure of sEMG active duration is robust  
27 across parameter choices (e.g., sampling rate, window length, threshold criteria), robust against  
28 typical noise sources present in paretic muscles (e.g., low signal-to-noise ratio, sporadic motor unit  
29 action potentials), and reliable across measurements (e.g., sensors, trials, and days), while  
30 providing a continuum of scale over the full magnitude range for each session. Furthermore, sEMG  
31 active duration could well characterize the clinically observed differences in hypertonia expressed  
32 across different muscles and impairment levels. The proposed measure can be used for continuous  
33 and quantitative monitoring of hypertonia during activities of daily living while at home, which  
34 will allow for the study of the practical effect of pharmacological and/or physical interventions  
35 that try to combat its presence.

## 36 1. INTRODUCTION

37 Upper extremity motor impairment after stroke is a major contributor to loss of function in daily  
38 life. Among many neurological conditions that impair control of the paretic arm, hypertonia,  
39 broadly defined as an increase in muscle tone, commonly appears in individuals with hemiplegic  
40 stroke [1, 2]. Hypertonia is clinically observed to be most prevalent in distal flexor muscles [1, 3,  
41 4]. Cumulating evidence suggests that hypertonia present in wrist and finger muscles may be  
42 linked to the upregulation of the corticoreticulospinal system following a loss of corticobulbar  
43 projections from the lesioned hemisphere [5]. As a result, individuals with severe motor  
44 impairment after stroke often have difficulties in using their hand, for example, opening the hand  
45 or extending the wrist, which is detrimental to many activities of daily living [6]. Studies suggest  
46 that prolonged exposure to such abnormal neural drive may further impact musculoskeletal  
47 changes in the paretic arm, leading to a flexed resting posture or contractures [7, 8]. Consequently,  
48 current treatment of hypertonia largely focuses on wrist/finger and sometimes elbow flexor  
49 muscles, which include focal injection of botulinum toxin [9-11], use of wrist/finger orthosis or  
50 splints [9, 12, 13], electrical stimulation [14], stretching [15, 16], and surgical procedures such as  
51 tendon transfers [17-19].

52 However, there currently is no quantitative measure that can be used to constantly track how  
53 hypertonia is expressed in wrist and fingers muscles, which is crucial for understanding the true  
54 impact of hypertonia in daily function or objectively assessing the effectiveness of afore-  
55 mentioned treatments, e.g., pre and post intervention. Hypertonia in clinic is currently assessed  
56 using coarse scores such as the Modified Ashworth Scale (MAS) [20-22] and the Modified Tardieu  
57 Scale [23]. On the other hand, many studies have also attempted to assess hypertonia more  
58 quantitatively using laboratory equipment (e.g., mechatronics combined with dynamometry,

59 sEMG) [16, 24]. However, such momentary measurements which largely relies on manual (in  
60 clinics) or instrumented (in laboratory) examination of passive resistance to joint displacement do  
61 not capture the true presence of hypertonia during daily activities. This is because daily  
62 involvement of the paretic arm is most often marked by non-use or neglect, while performing  
63 motor tasks with the non-paretic arm or the whole body [25, 26]. As such, there often is not a good  
64 correlation between these measures and patient's ratings of abnormal tone experienced daily [11,  
65 27, 28], and thus fail to provide useful information about the impact of hypertonia on everyday  
66 function.

67 Recent advances in wearable sensors, e.g., inertial measurement unit (IMU) + surface  
68 electromyography (sEMG), offer promising avenues to examine motor function of neurologically  
69 injured individuals in the real-world. As such, they have been employed in many applications in  
70 rehabilitation, e.g. to recognize motor pattern or intent for robotic prosthetics control [29-31], to  
71 detect disease symptoms or adverse events [32-34], or to provide bio-feedback during training  
72 [35]. However, there are remaining gaps in utilizing these technologies to constantly monitor an  
73 important neural signature underlying post-stroke motor impairment such as hypertonia. Most  
74 importantly, we currently lack a robust measure that can reliably quantify abnormal neural drive  
75 to paretic muscles over extended periods of time (e.g., weeks) [36, 37]. In particular, sensitivity  
76 of sEMG magnitude to noise and electrode placement makes it challenging to obtain consistent  
77 measurements across days [38-40]. For example, measurements via sEMG inherently suffers from  
78 nonstationarity of the signal, where magnitude of the signal varies with measurement condition  
79 such as electrode-skin impedance and electrode location. Further, deficits in stroke survivors to  
80 voluntarily activate their muscle raises issues in defining a reference for comparison [41-43].

81 In this study, we propose a novel time-based surface electromyography (sEMG) measure,  
82 Active Duration, which can overcome the limitations of the coarse clinical scales often measured  
83 in functionally irrelevant context and the challenges associated with magnitude-based sEMG  
84 measures to quantify hypertonia. We postulate that the key to robust quantification of hypertonia  
85 is to capture the “true” baseline in sEMG for each measurement session, by which we can define  
86 the length of time (i.e., duration) a muscle is active relative to this baseline using a widely accepted  
87 technique for detecting active state of a muscle from sEMG [44-46]. Such approach can be applied  
88 over a short time segment tracked in a sliding window fashion to quantify the continuous time-  
89 course of how and to what extent hypertonia is expressed, e.g., over extended period (hours) during  
90 activities of daily living. To validate the robustness of the proposed measure in real-world scenario,  
91 we first use sEMG from healthy individuals to test its robustness across parameter choices, against  
92 noise, and its reliability across measurements. Further, we demonstrate the feasibility and the  
93 utility of the proposed measure with sEMG recorded from paretic arm muscles while individuals  
94 with stroke perform various daily activities, such as, while awake, when completely relaxed, as  
95 well as during some functional activities such as ambulating in the laboratory. Results are further  
96 discussed focusing on the implications to quantifying hypertonia in paretic arm muscles during  
97 daily activities after stroke.

## 98 2. MATERIALS AND METHODS

### 99 2.1. *Active duration: a time-based sEMG measure to quantify hypertonia*

100 Our proposed time-based measure of hypertonia quantifies *Active Duration* of sEMG within a time  
101 segment, defined as the percent of time conditioned signal is above a threshold defined with signal  
102 distribution. Briefly, the method relies on robust capturing of the “true” baseline in sEMG for each  
103 measurement session using an established relaxation protocol (i.e., eliminate hyperactivity) [47,  
104 48], from which we define the relative duration of activity over a short time segment, continuously  
105 tracked in a sliding window fashion (Fig. 1A). Specifically, four steps are involved:

106 1) Signal pre-processing and conditioning: Raw sEMG recorded from any muscle or channel  
107 can be pre-processed to first remove any noise known or identified to be present such as  
108 offset, powerline interference, or substantial motion artifact. Then, the signal is conditioned  
109 with Teager-Kaiser energy operator (TKEO) to improve signal-to-noise ratio [44-46]:

$$110 \quad \Psi[x(n)] = x(n)^2 - x(n+1) \cdot x(n-1),$$

111 where  $x(n)$  denotes  $n$ th sample of the processed sEMG signal. Conditioned sEMG is then  
112 full-wave rectified.

113 2) Defining the segment-based minimum across all recordings (Fig. 1A, top): Processed and  
114 conditioned sEMG is examined with moving average window with a given length ( $WL$ )  
115 and overlap (in %) to find the minimum ( $\mu$ ) across all recordings for a given muscle. Here,  
116  $WL$  and overlap are custom parameters that determine the temporal resolution of the final  
117 active duration measure (see section 2.2 below), just as any time-domain smoothing  
118 process would do, which also affects the computational demand (e.g., the smaller the  $WL$   
119 and greater the overlap, the greater the demand).

120 3) Defining the threshold criteria (Fig. 1A, middle): For the segment where minimum mean  
121 ( $\mu$ ) was found above, standard deviation ( $\sigma$ ) is calculated. The threshold criterion ( $TC$ ) for  
122 defining active state of a muscle is defined as:

$$123 \quad TC = \mu + N\sigma,$$

124 where  $N$  is the multiplication factor, which is a widely used method for detecting the onset  
125 in sEMG signals [44-46]. This factor  $N$  determines the sensitivity in detecting an active  
126 state, where ranges of numbers have been used or tested in literature [44-46], e.g., 1-3 and  
127 3-23 for sEMG without and with TKEO conditioning, respectively. For the proposed  
128 measure active duration,  $TC$  determines the lower bound and the relative mapping to the  
129 signal magnitude (see section 2.2. below). While larger  $TC$  (e.g.,  $\mu+8\sigma$ ) is often used to  
130 detect EMG onset during voluntary movements in healthy individuals [44-46], for paretic  
131 muscles where signal-to-noise ratio (SNR) is often expected to be very low [49, 50],  
132 smaller  $TC$  (e.g.,  $\mu+3\sigma$ ) is recommended to more robustly capture the hyperactive muscle  
133 tone.

134 4) Active duration calculation (Fig. 1A, bottom): Once  $TC$  is defined from the previous step,  
135 this can be used to count, on segment basis (window length:  $WL$ ), the number of datapoints  
136 that are above the threshold in percentage of time.

137 Results from segments in consideration can be then used to construct a continuous, time-course  
138 of active duration of sEMG, at given temporal resolution as determined by  $WL$  and overlap, where  
139 a different overlap interval can be used than in step 2), depending on the purpose. For example,  
140 one may choose to use greater overlap for more smooth and continuous visualization, whereas use  
141 results with no overlap to ensure statistical independence in analyzing time-series data [51]. An

142 example with  $WL=5$  s and  $N=3$  (i.e.,  $TC=\mu+3\sigma$ ) shows, active duration over 60 s when an  
143 individual with stroke was performing various activities of daily living (see section 2.3 for detail).

144

## 145 **2.2. Validating robustness and reliability of active duration measure**

146 To validate the sEMG active duration as a useful and reliable measure for daily monitoring or  
147 tracking of hypertonia in home-based setting, we first used experimental data from healthy  
148 individuals to systematically examine the sensitivity of sEMG active duration in detecting neural  
149 drive to muscles and quantifying the degree in relation to signal magnitude (or power).  
150 Specifically, we assessed the robustness of the proposed measure across parameter choices and  
151 against simulated noise, and its reliability across measurements conditions.

### 152 2.2.1. Experimental protocol and setup

153 Total six healthy young adults (age 24-29 years; 3 females) participated. All participants gave  
154 informed consent prior to the experiment. All procedures and protocols were approved by the  
155 Northwestern University Institutional Review Board.

156 Participants completed two sessions, apart by a week on average ( $6.8\pm 4.3$  days), repeating the  
157 same protocol. Each day (session), participants performed series of motor tasks mimicking  
158 activities of daily living (ADL). While we ultimately seek to apply the method during any ADL,  
159 for validation purposes here, we used standardized protocols that closely mimic ADL and represent  
160 typical states of daily arm involvement and engaging sub-maximal level of muscle activation in a  
161 controlled way.

- 162 • Baseline: This task represented a completely *relaxed* state, e.g., when a participant is  
163 asleep/nearly asleep, where in the case of individuals with stroke, abnormal tone or  
164 hypertonia is expected not to be present, providing a “true” baseline. For healthy



165 individuals, however, complete relaxation is readily achievable. During baseline,  
166 participants were seated on a standard chair with arm naturally supported on laps for 2.5  
167 minutes.

- 168 • Timed Up and Go (TUG): This task represented the *ambulatory* state which involves a  
169 functional, whole-body movement. TUG is a clinical test designed to assess basic mobility  
170 in neurologically impaired individuals [52, 53]. The test is comprised of a sequence of  
171 functional maneuvers including rising from a chair (at the verbal cue ‘Go’), walking 3  
172 meters (distance indicated by a line on floor to cross), walking back, and sitting down  
173 again. In the case of individuals with hemiparetic stroke, participants are allowed to use  
174 customary walking aids (e.g., cane) used in daily living.
- 175 • Timed Dumbbell (TD): This task is designed to have participants activate different groups  
176 of muscles at a controlled level, while performing a set of isotonic dumbbell-lifting (3  
177 different weights) with their dominant (right) arm in a standardized manner, synchronized  
178 to a digital metronome with visual and audio feedback in real time. The 3 set of weights  
179 were selected for each participant, prior to the actual experiment, at levels that will engage  
180 at least perceivable effort but not inducing any fatigue and was used consistently across the  
181 two sessions for each participant. The TD tasks targeted various Degrees of Freedom  
182 (DoF), including wrist flexion/extension (WF/WE), elbow flexion/extension (EF/EE), and  
183 shoulder abduction (ABD), each repeated 7 times (see Table 1. for detailed procedure).
- 184 • Maximum Voluntary Contraction (MVC): MVCs for wrist flexion/extension (WF/WE),  
185 elbow flexion/extension (EF/EE), and shoulder abduction (ABD) were performed to  
186 capture the maximum level of voluntary muscle activation for each session. To control for  
187 consistent posture across sessions and provide support (restraint) for engaging maximal

188 effort, participants were seated on the Biodex chair (Biodex Medical Systems, Inc., Shirley,  
189 New York, USA), with apertures fixed at similar range across participants while  
190 accommodating for each participant's comfort (Fig. 2B), which was kept consistent across  
191 sessions. MVC trial for each DoF lasted about 5 s each, encouraged by verbal stimuli, and  
192 were repeated 3 times, with sufficient breaks in between.

- 193 • All procedures were instructed and administered by the same licensed physical therapist to  
194 ensure consistency and repeatability.

195 Participants repeated the sequence of Baseline, TUG, and TD three times, with consecutively  
196 increasing weights in the TD tasks. MVC trials were completed at the end of the experiment. This  
197 order was devised to minimize the influence of potential fatigue, which was also monitored  
198 through verbal communication with the participant.

199 During each trial in all sessions, muscle activity was recorded at 2 kHz from the given set of  
200 target muscles across the wrist/finger, elbow, and shoulder joints (see Fig. 2 and Table 1 for  
201 detailed list and abbreviations) from the dominant (right) arm using a wireless sEMG system  
202 (Delsys Trigno™, Delsys, Natick, MA). Raw sEMG signals were manually inspected to remove  
203 any artifact or noise including powerline interference in a consistent manner using an auto-  
204 regression modeling [54] and a spectral interpolation technique [55]. In addition, tri-axial  
205 acceleration and angular rate were recorded (148.148 Hz, synchronize with sEMG signal at 2:27  
206 ratio) with inertial measurement unit (IMU) sensors attached at the trunk (sternum), elbow  
207 (proximal to olecranon fossa), and forearm (ulnar-radial styloid) (Fig. 2). IMU signals were further  
208 low-pass filtered with zero-phase Butterworth filter (4th order) at 10 Hz cut-off frequency, which  
209 were used to detect and segment sEMG data according to each task.

210 Between the two sessions, two different sets of sensor elements were used (assigned in random  
211 order across participants) to incorporate potential differences between elements/channels, in  
212 addition to natural inter-day variability across measurement days (see section 2.2.4).

213

#### 214 2.2.2. Robustness across parameter choices

215 Ranges of selected parameters involved in calculation of sEMG active duration (see section 2.1.)  
216 were tested. First, to examine the effect of window length ( $WL$ ), which determines the temporal  
217 resolution of resulting active duration calculated, we tested  $WL$  of 0.5, 1, 2, and 5 s. This parameter  
218 can be also customized depending on the type of task being examine, e.g., slow/static vs.  
219 fast/dynamic, or computational demand such as memory and data storage size.

220 To emulate different sensor specification and re-sampling processes that may be potentially  
221 used, we tested sampling rates of 200 Hz, 400 Hz, 1kHz, and 2 kHz by decimating (with lowpass  
222 Chebyshev Type I infinite impulse response filter of order 8, to prevent aliasing during down-  
223 sampling) at ratio 1/10, 1/5, 1/2, and 1 of the original signal at 2 kHz, respectively.

224 To examine the effect of threshold criteria ( $TC$ ) that defines the active state of a muscle, we  
225 tested the multiplication factor  $N$  (where  $TC = \mu + N\sigma$ ) of 2, 3, 5, and 10.

226 In all cases, when the parameter of interest was systematically varied, other parameters were  
227 kept constant, which were selected as  $WL=2$  s, sampling rate = 2 kHz, and  $N=3$  as default.

228 Finally, we were also interested in investigating the relationship between the proposed measure  
229 and the magnitude (or power) of the signal, we examined the shape of the one-to-one mapping  
230 between the sEMG active duration and root mean square (RMS) calculated with corresponding  
231 parameter (s) on segment basis. Specifically, the initial slope (at low level) and the minimum offset  
232 of this curve was used to determine the sensitivity and consistency of sEMG active duration in

233 detecting the onset state of a muscle, respectively. On the other hand, the range spanned and the  
234 general shape from minimum to maximum value was used to determine the extent to which and  
235 how sEMG active duration spanned the range of magnitudes (i.e., RMS).

236

### 237 2.2.3. Robustness against simulated noises

238 Because our method is targeted to quantify the sEMG active duration in paretic muscles, where  
239 low SNR (i.e., due to paresis and deficit in voluntary activation [41-43]) and presence of abnormal  
240 neural drive (e.g., involuntary, sporadic firing [56]) are expected, we emulated such conditions by  
241 injecting simulated noise to the sEMG recorded from healthy individuals. In particular, we tested  
242 robustness of resulting sEMG active duration against two types of noise. First, we simulated  
243 overall increased background noise level in a muscle or a channel by injecting gaussian white noise  
244 with varying SNR 1, 2, 5, 10, and 20 dB, generated with built-in function 'awgn.m' in Matlab  
245 (Mathworks, Natick, MA), in which the power of the input (clean) signal is estimated using the  
246 data from representative trials of each type concatenated for each muscle/channel.

247 In addition, to model the sporadic motor unit firing patterns with varying statistical  
248 characteristics, we employed the model developed by Konstantin et al., [57], where parameters  
249 were modified for muscles and the sEMG data examined in this study. Briefly, the model allows  
250 for simulating synthesized sEMG signals mainly driven by the excitation profile for the motor  
251 neuronal pool, while incorporating realistic motor neuron behavior, muscle fiber innervation  
252 geometry, and tetanic force development [57]. Specifically, to test whether sEMG active duration  
253 has the sensitivity to capture the statistical characteristics of motor unit action potential, we used  
254 two types of excitation profiles (Fig. 4B, in section 3): trapezoid (15s ramp up - 15 s hold - 15s  
255 ramp down) and constant with varying firing rate (at default, 1/2, and 1/5 frequency). The

256 synthesized EMGs were then superimposed onto the experimental sEMG data from the Baseline  
257 trials, to calculate the resulting active duration.

258

#### 259 2.2.4. Reliability across measurements

260 Finally, we tested the reliability of sEMG active duration measured between two different sessions,  
261 naturally affected by inter-day variability and different set of sensor elements within an individual.  
262 Reliability was assessed with an intraclass correlation coefficient (ICC, excellent when  $\geq 0.90$ ,  
263 good when  $0.75 \leq \text{ICC} < 0.90$ , moderate when  $0.50 \leq \text{ICC} < 0.75$ , and poor when  $\text{ICC} < 0.50$  [58]),  
264 where 3 repetitions for each type of task in each day were considered as random effect. To this  
265 end, data from each task type was segmented to consistent length and aligned in time (using IMU  
266 signals) between the two days, which encapsulated the main task in the middle. Selected lengths  
267 for Baseline, TUG, TD, and MVC trials were 65, 35, 103, and 20 s, respectively.

268

### 269 **2.3. *Demonstrating feasibility and utility in paretic muscles***

#### 270 2.3.1. Experimental protocol and setup

271 Total three individuals with chronic hemiparetic stroke ( $22.0 \pm 10.5$  years post stroke; age  $62.7 \pm 7.5$ ;  
272 2 females) participated. We recruited participants who had varying levels of motor impairment, as  
273 assessed by Fugl-Meyer Assessment upper extremity portion (FMA-UE) [61], with scores apart  
274 by minimal clinically important differences [59]. All participants gave informed consent prior to  
275 the experiment. All procedures and protocols were approved by the Northwestern University  
276 Institutional Review Board.

277 Participants performed daily motor tasks similar to the previously described protocol (in  
278 section 2.2). However, to distinguish the baseline state when hypertonia is present or absent, we

279 used three different states. *Relaxed* state represents when participant is asleep/nearly asleep.  
280 Following an established protocol to maximally relax paretic muscles [60], participants sat  
281 comfortably on a supported/reclined chair in a dark quiet room with relaxing music for 15  
282 minutes. *Awake* state represents sedentary [61, 62], yet awake condition with paretic arm at rest.  
283 Participants were seated on a standard chair with paretic arm naturally supported. *Ambulatory* state  
284 represents involvement of the paretic arm during whole-body, functional task. Participants  
285 performed the TUG test, as described before. While MVC were collected for reference, data from  
286 these trials were not included in the analysis (see below) because individuals have difficulty in  
287 voluntarily activating the muscles, especially with more severe motor impairments [41-43].  
288 Indeed, it was found that the magnitude of muscle activity in some participants were greater when  
289 involuntary drive was present than those observed during the MVC trials. All procedures,  
290 including the clinical test (FMA-UE) were administered by licensed physical therapist.

291 During the experiment, sEMG and IMU data were collected as previously described, however,  
292 using a subset of muscles for sEMG, excluding the three shoulder muscles as hypertonia is less  
293 prevalent in these proximal muscles.

294

### 295 2.3.2. Analysis

296 Our main focus was to test whether the proposed measure sEMG active duration can characterize  
297 the clinically observed differences in hypertonia expressed across different muscles and  
298 impairment levels well. Specifically, based on the well-known clinical observations and findings  
299 on prevalence of hypertonia [1, 3, 4], we hypothesized that active duration is greater in distal, than  
300 in proximal muscles, and increases with the severity of impairment level. To test this hypothesis,  
301 we used a linear mixed-effects model with active duration as dependent variable, and state (3

302 levels: *Relaxed*, *Awake*, and *Ambulatory*; see section 2.3.1), joint (2 levels: distal, proximal), and  
303 impairment level (i.e., FMA-UE) as fixed effects, and subject and muscle as random effects.

304 **3. RESULTS AND DISCUSSIONS**

305 **3.1. Validation of sEMG active duration measure**

306 For brevity and clarity, here we report and discuss only the examples from a representative  
307 participant and muscle TRI. Nevertheless, results were consistent across all muscles and all  
308 participants. All data and codes are available upon proper request to the corresponding author.

309 3.1.1. Robustness across parameter choices

310 We found that the proposed measure was robust across parameter choices (Fig. 3). For example,  
311 using larger window length had smoothing effect, as would be expected for magnitude-based  
312 measure such as RMS (Fig. 3A, top left two). In relation to magnitude (Fig. 3A, right), RMS  
313 normalized to 100% at MVC, sEMG active duration sensitively (i.e., sharp initial slope) and  
314 robustly (i.e., consistent minimum offset) captured the active state of a muscle, lateral head of the  
315 triceps (TRI) in this case, while still providing a continuum of scale over the full magnitude range  
316 (i.e., range span from near-zero to 100%) in a nonlinear fashion, which asymptotically saturates at  
317 ~25% RMS, however with a clearly distinguishable curve even beyond.

318 Testing across range of other parameters, such as sampling rate (Fig. 3B) and threshold criteria  
319 (Fig. 3B), also demonstrated that the method may allow for parameter optimization among various  
320 sensor configurations and tasks.

321 Robustness of the proposed measure sEMG active duration across ranges of various parameters  
322 confer reliable quantification of hypertonia across time, at both spatial and temporal resolution far  
323 exceeding the current, momentary measures in clinic- [20-22] or laboratory-based settings [16,  
324 24]. Moreover, wider range of possible sEMG sensor configuration, e.g., low sampling rate, will  
325 allow for the use of more power-efficient sensor systems, that are more well-suited for real-world  
326 deployment, e.g., for daily use at home, outside the laboratory [32-34].



327

### 328 3.1.2. Robustness against simulated noise sources

329 In addition, the proposed measure was robust against typical noise sources present in paretic  
330 muscles. When contaminated with gaussian white noise with varying SNR, the sEMG active  
331 duration could still sensitively and robustly capture active state of a muscle (Fig. 4A, left). In the  
332 case of RMS, in contrast, much of the signal was buried with low SNR (Fig. 4A, middle), which  
333 would be problematic especially when applied to muscles with substantial paresis [41-43].  
334 Relationship to magnitude became more linear and spanned lesser range with lower SNR, however  
335 while still providing a continuum of scale that can be mapped to 0 to 100% RMS (Fig. 4A, right).

336 When we simulated noise that mimic sporadic motor neuron action potentials often observed  
337 in a paretic muscle, the change in temporal profile of the sEMG active duration from Baseline  
338 closely followed the excitation profile, and thus the statistical characteristics of motor unit firing  
339 or recruitment (Fig. 4B, right). The magnitude-based measure RMS, on the other hand, rather  
340 represented the amplitude of the injected noise (Fig. 4B, left), indicating that it will be subjected  
341 to ignoring the low-level manifestation of hypertonia as small offset (or noise) in background.

342 While pathological pattern of muscle activity has been often considered as noise or practical  
343 barriers in using magnitude-based sEMS measures [63, 64], our results suggest that sEMG active  
344 duration may be useful for examining important neuropathological characteristics of paretic  
345 muscle recruitment. Increased involuntary muscle tone (i.e., hypertonia) makes limb movement  
346 difficult and is influenced by the need/demand/intention to use the paretic/nonparetic limb or the  
347 whole body [65-67]. Evidence further suggests that the same neural mechanism, upregulation of  
348 corticoreticulospinal system due to the lost corticofugal projections [68-70], underlies the  
349 manifestation of abnormal drive to paretic muscles in various forms, resulting in the expression of

350 the flexion synergy [71-73], spasticity [74], associated reactions [75], paresis (resulting in ‘learned  
351 non-use’ [76]) and associated functional motor deficits. Thus, provided with the exact real-world  
352 context in which such deficits are experienced and manifested, the sEMG active duration can be a  
353 useful measure to probe into the true impact of abnormal neural drive and resulting motor  
354 impairments during activities of daily living.

355

### 356 3.1.3. Reliability across measurements

357 Finally, we also found that the proposed measure sEMG active duration is reliable across  
358 measurements, i.e., repetitions within a day as well as across days. For example, the time trace of  
359 3 repetitions of the same task in the same session for each Day 1 (Fig. 5A, left) and Day 2 (Fig.  
360 5A, right) were highly repeatable, both within days as well as across days. Inter-day reliability of  
361 sEMG active duration was also excellent, resulting in intra-class correlation coefficient over 0.99  
362 in most muscles examined (Fig. 5B). Especially, the near-zero% value at the Baseline and near-  
363 100% value at MVC were very consistent, which was the case for all muscles and individuals.  
364 This result indicates that the measure (e.g., with default parameters selected in this study) provides  
365 highly reliable and consistent lower and upper bounds that is comparable across muscles and  
366 individuals, in stark contrast to magnitude-based sEMG measures that suffer from normalization  
367 issues [41-43].

368 Furthermore, such high reliability across measurement days suggest that the sEMG active  
369 duration can be a solution to the remaining challenges in using sEMG signal to obtain robust  
370 measurements over extended period of time, e.g. across days or weeks [36, 37].


371

372 **3.2. Feasibility and utility in paretic muscle: preliminary results**

373 Our preliminary results (n=3) demonstrate that the proposed, time-based measure sEMG active  
374 duration can well characterize the clinically observed differences in hypertonia expressed across  
375 different muscles and impairment levels (Fig. 6). Using this measure, we found that hypertonia  
376 was more prevalent (i.e., active for longer duration) in distal wrist/finger muscles than proximal  
377 elbow muscles during *Awake* ( $t_{254}=5.45$ ,  $p<10^{-6}$ ) and *Ambulatory* states ( $t_{282}=3.54$ ,  $p<0.001$ ).  
378 Importantly, however, there was no difference across muscles ( $t_{254}=0.99$ ,  $p=0.32$ ) or subjects  
379 (insignificant random effect) during completely *Relaxed* state (Fig. 6A), indicating that our  
380 relaxation protocol [60] successfully quieted all muscles, and that our measure robustly quantifies  
381 the “true” baseline that is consistent/comparable across muscles and subjects, which was not the  
382 case with magnitude-based measures (e.g., RMS, normalized to MVCs). Furthermore, the amount  
383 of reduction in active duration from *Awake* to *Relaxed* state, i.e., difference between “nominal”  
384 and “true” baseline, increased as a function of impairment level (FMA-UE), more so in distal  
385 muscles (Fig. 6B;  $t_{254}=-3.51$ ,  $p<0.001$ ), indicating that individuals with more severe impairment  
386 would experience a longer period of continuous involuntary activity, especially in the distal  
387 muscles, even during an ordinary resting state while awake.


388 **4. CONCLUSIONS**

389 Here, we presented the work aimed at developing a time-based surface EMG measure that can be  
390 used to track stroke-induced hypertonia during activities of daily living. We validated that the  
391 sEMG active duration measure is robust across parameter choices (e.g., sampling rate, window  
392 length, threshold criteria), robust against typical noise sources present in paretic muscles (e.g., low  
393 signal-to-noise ratio, sporadic motor unit action potentials), and reliable across measurements  
394 (e.g., sensors, trials, and days), while providing a continuum of scale over the full magnitude range  
395 for each session. Furthermore, sEMG active duration could well characterize the clinically  
396 observed differences in hypertonia expressed across different muscles and impairment levels.  
397 Taken together, this novel time-based measure is well-suited for continuous and quantitative  
398 monitoring of hypertonia in the real-world, e.g., while at home, when integrated with commercially  
399 available wearable sensors that are easy-to-use (easy-to-“don and dof” and “wear”) [77]. Such a  
400 monitoring system will allow for the study of practical effect of pharmacological and/or physical  
401 interventions and facilitate the investigation of daily impact of hypertonia and its underlying neural  
402 mechanisms.




403

404 **Figure 1.** Proposed time-based sEMG measure: Active duration. (A) Conditioned sEMG is  
 405 examined with a moving average window (e.g., 5 s) to find the minimum across all recordings  
 406 (top), from which a threshold of active state was defined (middle). Active duration is calculated  
 407 for each segment as the percent of time amplitude was above the threshold (bottom). (B) Time  
 408 trace of conditioned sEMG and calculated active duration (bottom) over 60 s from a representative  
 409 participant with stroke during normal *Awake*, completely *Relaxed*, and functional *Ambulatory*  
 410 states.




411

412 **Figure 2.** Sensor placement. Muscle activity (sEMG) was recorded from 3 shoulder (orange), 2  
 413 elbow (red), and 6 wrist/hand (purple) muscles. IMU data was recorded from two locations (trunk  
 414 and wrist) to monitor gross movement and to segment sEMG data based on event detection.



415

416 **Figure 3.** Robustness across parameter choices. (A) Resulting sEMG active duration (left) and  
 417 corresponding RMS (middle) for various motor tasks, when window length is systematically  
 418 varied. The relationship between active duration and RMS represented as the one-to-one mapping  
 419 of active duration and RMS on segment basis (right). (B) Resulting sEMG active duration when  
 420 sampling rate is systematically varied. (C) Resulting sEMG active duration when threshold criteria  
 421 are systematically varied.



423 **Figure 4.** Robustness against simulated noise sources. (A) Resulting sEMG active duration (left)

424 and corresponding RMS (middle) for various motor tasks, when background noise with varying


425 signal-to-noise ratios (SNR) are added. The relationship between active duration and RMS (right).

426 (B) Resulting sEMG active duration (left) and corresponding RMS (right), when simulated EMG

427 with sporadic motor unit action potentials with varying statistical characteristics (top) are added to


428 sEMG during baseline.





429

430 **Figure 5.** Reliability across measurements. (A) Active duration calculated for various tasks during  
 431 three repetitions within a day, and across two sessions Day 1 (left) and Day 2 (right), that was apart  
 432 by 3 days. Error bars indicate standard error (SE). (B) Inter-day reliability, as measured by intra-  
 433 class correlation coefficient (ICC). (C) ICC for other four muscles for the same representative  
 434 participant are displayed.



435

436 **Figure 6.** Preliminary results with individuals with stroke (n=3), with varying level of impairment  
 437 (FMA-UE). (A) Comparison of sEMG active duration between distal wrist and proximal elbow  
 438 muscles during *Awake*, *Relaxed*, and *Ambulatory* states. Each data point indicates mean $\pm$ SE across  
 439 12 segments for each muscle in each state. (B) Amount of reduced time active in *Relaxed* relative  
 440 to *Awake* state, as a function of impairment level (FMA-UE).

**Table 1.** Target muscle list for sEMG recording

Joints	Muscles	Abbrev.
Wrist	<i>Flexor carpi radialis</i>	FCR
	<i>Flexor digitorum superficialis</i>	FDS
	<i>Flexor carpi ulnaris</i>	FCU
	<i>Extensor carpi radialis</i>	ECR
	<i>Extensor digitorum communis</i>	EDC
	<i>Extensor carpi ulnaris</i>	ECU
Elbow	<i>Biceps brachii</i>	BIC
	<i>Triceps brachii lateral head</i>	TRI
Shoulder	<i>Anterior deltoid</i>	AD
	<i>Middle deltoid</i>	MD
	<i>Posterior deltoid</i>	PD

**Table 2.** Description of detailed protocols for each DoF

DoF	TD task procedure*
Wrist flexion (WF)	Upper arm on side, elbow 90°, forearm supinated with palm facing superior (up), begin from fully down (extended), 7 cycles of down-up-down at 90 BPM**
Wrist extension (WE)	Upper arm on side, elbow 90°, forearm pronated with palm facing inferior (down), begin from fully down (flexed), 7 cycles of down-up-down at 90 BPM
Elbow flexion (EF)	Upper arm on side, forearm supinated with palm facing anterior, begin from elbow fully extended (0°), 7 cycles of elbow 0°-150° (fully flexed)-0° at 70 BPM
Elbow extension (EE)	Upper arm raised on side, forearm pronated with palm facing anterior, begin from elbow fully extended (0°), 7 cycles of elbow 0°-150° (fully flexed, behind the head)-0° at 70 BPM
Shoulder abduction (Abd)	Begin from arm on side, forearm in neutral with palm facing medial, keep elbow fully extended (0°) and forearm neutral, 7 cycles of shoulder 0°-90° (prior to elevation)-0° abduction at 70 BPM

\*\* In all cases, participants were instructed to “use only as much effort needed”.

\* BPM: bit per minute.

443 **Supplementary Materials:** N/A.

444 **Author Contributions:** Conceptualization, M.H.S.; methodology, M.H.S. and J.D.; software,  
445 M.H.S.; validation, M.H.S. and J.P.A.D.; formal analysis, M.H.S.; investigation, M.H.S. and J.D.;  
446 resources, J.P.A.D.; data curation, M.H.S.; writing—original draft preparation, M.H.S.; writing—  
447 review and editing, M.H.S, J.D., and J.P.A.D.; visualization, M.H.S.; supervision, M.H.S. and  
448 J.P.A.D.; project administration, J.D. and J.P.A.D.; funding acquisition, J.P.A.D. All authors have  
449 read and agreed to the published version of the manuscript.

450 **Funding:** This research was funded by Department funds to M.H.S. and J.D., the NIH  
451 R01NS105759 to J.P.A.D. and the NIHR01HD084009 to J.P.A.D. and W.M.M

452 **Institutional Review Board Statement:** Not applicable.

453 **Data Availability Statement:** All data and codes used in this paper are available on proper request  
454 to the corresponding author: [hogchul.sohn@northwestern.edu](mailto:hogchul.sohn@northwestern.edu).

455 **Acknowledgments:** Any support given which is not covered by the author contribution or funding  
456 sections, e.g., administrative and technical support, or donations in kind.

457 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the  
458 design of the study; in the collection, analyses, or interpretation of data; in the writing of the  
459 manuscript, or in the decision to publish the results.

460 **REFERENCES**

- 461 1. Marciniak, C. "Poststroke Hypertonicity: Upper Limb Assessment and Treatment." *Top*  
 462 *Stroke Rehabil* 18, no. 3 (2011): 179-94.
- 463 2. Sheean, G., and J. R. McGuire. "Spastic Hypertonia and Movement Disorders:  
 464 Pathophysiology, Clinical Presentation, and Quantification." *PM R* 1, no. 9 (2009): 827-  
 465 33.
- 466 3. Li, S., D. G. Kamper, and W. Z. Rymer. "Effects of Changing Wrist Positions on Finger  
 467 Flexor Hypertonia in Stroke Survivors." *Muscle Nerve* 33, no. 2 (2006): 183-90.
- 468 4. Twitchell, T. E. "The Restoration of Motor Function Following Hemiplegia in Man." *Brain*  
 469 74, no. 4 (1951): 443-80.
- 470 5. McPherson, J. G., M. D. Ellis, C. J. Heckman, and J. P. Dewald. "Evidence for Increased  
 471 Activation of Persistent Inward Currents in Individuals with Chronic Hemiparetic Stroke."  
 472 *J Neurophysiol* 100, no. 6 (2008): 3236-43.
- 473 6. Broeks, J. G., G. J. Lankhorst, K. Rumping, and A. J. Prevo. "The Long-Term Outcome of  
 474 Arm Function after Stroke: Results of a Follow-up Study." *Disabil Rehabil* 21, no. 8  
 475 (1999): 357-64.
- 476 7. Metoki, N., Y. Sato, K. Satoh, K. Okumura, and J. Iwamoto. "Muscular Atrophy in the  
 477 Hemiplegic Thigh in Patients after Stroke." *Am J Phys Med Rehabil* 82, no. 11 (2003):  
 478 862-5.
- 479 8. O'Dwyer, N. J., L. Ada, and P. D. Neilson. "Spasticity and Muscle Contracture Following  
 480 Stroke." *Brain* 119 ( Pt 5) (1996): 1737-49.
- 481 9. Yasar, E., F. Tok, I. Safaz, B. Balaban, B. Yilmaz, and R. Alaca. "The Efficacy of Serial  
 482 Casting after Botulinum Toxin Type a Injection in Improving Equinovarus Deformity in  
 483 Patients with Chronic Stroke." *Brain Inj* 24, no. 5 (2010): 736-9.
- 484 10. Bakheit, A. M., A. F. Thilmann, A. B. Ward, W. Poewe, J. Wissel, J. Muller, R. Benecke,  
 485 C. Collin, F. Muller, C. D. Ward, and C. Neumann. "A Randomized, Double-Blind,  
 486 Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three  
 487 Doses of Botulinum Toxin Type a (Dysport) with Placebo in Upper Limb Spasticity after  
 488 Stroke." *Stroke* 31, no. 10 (2000): 2402-6.
- 489 11. Simpson, D. M., D. N. Alexander, C. F. O'Brien, M. Tagliati, A. S. Aswad, J. M. Leon, J.  
 490 Gibson, J. M. Mordaunt, and E. P. Monaghan. "Botulinum Toxin Type a in the Treatment  
 491 of Upper Extremity Spasticity: A Randomized, Double-Blind, Placebo-Controlled Trial."  
 492 *Neurology* 46, no. 5 (1996): 1306-10.
- 493 12. Popovic, D., A. Stojanovic, A. Pjanovic, S. Radosavljevic, M. Popovic, S. Jovic, and D.  
 494 Vulovic. "Clinical Evaluation of the Bionic Glove." *Arch Phys Med Rehabil* 80, no. 3  
 495 (1999): 299-304.
- 496 13. Doucet, B. M., and J. A. Mettler. "Effects of a Dynamic Progressive Orthotic Intervention  
 497 for Chronic Hemiplegia: A Case Series." *J Hand Ther* 26, no. 2 (2013): 139-46; quiz 47.
- 498 14. Leung, J., L. A. Harvey, A. M. Moseley, C. Tse, J. Bryant, S. Wyndham, and S. Barry.  
 499 "Electrical Stimulation and Splinting Were Not Clearly More Effective Than Splinting  
 500 Alone for Contracture Management after Acquired Brain Injury: A Randomised Trial." *J*  
 501 *Physiother* 58, no. 4 (2012): 231-40.
- 502 15. Selles, R. W., X. Li, F. Lin, S. G. Chung, E. J. Roth, and L. Q. Zhang. "Feedback-  
 503 Controlled and Programmed Stretching of the Ankle Plantarflexors and Dorsiflexors in

- 504 Stroke: Effects of a 4-Week Intervention Program." *Arch Phys Med Rehabil* 86, no. 12  
505 (2005): 2330-6.
- 506 16. Yeh, C. Y., J. J. Chen, and K. H. Tsai. "Quantifying the Effectiveness of the Sustained  
507 Muscle Stretching Treatments in Stroke Patients with Ankle Hypertonia." *J Electromyogr*  
508 *Kinesiol* 17, no. 4 (2007): 453-61.
- 509 17. Peraut, E., L. Taieb, C. Jourdan, F. Coroian, I. Laffont, M. Chammas, and B. Coulet.  
510 "Results and Complications of Superficialis-to-Profundus Tendon Transfer in Brain-  
511 Damaged Patients, a Series of 26 Patients." *Orthop Traumatol Surg Res* 104, no. 1 (2018):  
512 121-26.
- 513 18. Keenan, M. A., J. I. Korchek, M. J. Botte, C. W. Smith, and D. E. Garland. "Results of  
514 Transfer of the Flexor Digitorum Superficialis Tendons to the Flexor Digitorum Profundus  
515 Tendons in Adults with Acquired Spasticity of the Hand." *J Bone Joint Surg Am* 69, no. 8  
516 (1987): 1127-32.
- 517 19. Braun, R. M., G. T. Vise, and B. Roper. "Preliminary Experience with Superficialis-to-  
518 Profundus Tendon Transfer in the Hemiplegic Upper Extremity." *J Bone Joint Surg Am*  
519 56, no. 3 (1974): 466-72.
- 520 20. Bohannon, R. W., and M. B. Smith. "Interrater Reliability of a Modified Ashworth Scale  
521 of Muscle Spasticity." *Phys Ther* 67, no. 2 (1987): 206-7.
- 522 21. Pandyan, A. D., G. R. Johnson, C. I. Price, R. H. Curless, M. P. Barnes, and H. Rodgers.  
523 "A Review of the Properties and Limitations of the Ashworth and Modified Ashworth  
524 Scales as Measures of Spasticity." *Clin Rehabil* 13, no. 5 (1999): 373-83.
- 525 22. Platz, T., C. Eickhof, G. Nuyens, and P. Vuadens. "Clinical Scales for the Assessment of  
526 Spasticity, Associated Phenomena, and Function: A Systematic Review of the Literature."  
527 *Disabil Rehabil* 27, no. 1-2 (2005): 7-18.
- 528 23. Ansari, N. N., S. Naghdi, S. Hasson, M. H. Azarsa, and S. Azarnia. "The Modified Tardieu  
529 Scale for the Measurement of Elbow Flexor Spasticity in Adult Patients with Hemiplegia."  
530 *Brain Inj* 22, no. 13-14 (2008): 1007-12.
- 531 24. Katz, R. T., G. P. Rovai, C. Brait, and W. Z. Rymer. "Objective Quantification of Spastic  
532 Hypertonia: Correlation with Clinical Findings." *Arch Phys Med Rehabil* 73, no. 4 (1992):  
533 339-47.
- 534 25. Derungs, A., C. Schuster-Amft, and O. Amft. "Physical Activity Comparison between  
535 Body Sides in Hemiparetic Patients Using Wearable Motion Sensors in Free-Living and  
536 Therapy: A Case Series." *Front Bioeng Biotechnol* 6 (2018): 136.
- 537 26. Ezeugwu, V. E., and P. J. Manns. "Sleep Duration, Sedentary Behavior, Physical Activity,  
538 and Quality of Life after Inpatient Stroke Rehabilitation." *J Stroke Cerebrovasc Dis* 26, no.  
539 9 (2017): 2004-12.
- 540 27. Burridge, J. H., D. E. Wood, H. J. Hermens, G. E. Voerman, G. R. Johnson, F. van Wijck,  
541 T. Platz, M. Gregoric, R. Hitchcock, and A. D. Pandyan. "Theoretical and Methodological  
542 Considerations in the Measurement of Spasticity." *Disabil Rehabil* 27, no. 1-2 (2005): 69-  
543 80.
- 544 28. Lechner, H. E., A. Frotzler, and P. Eser. "Relationship between Self- and Clinically Rated  
545 Spasticity in Spinal Cord Injury." *Arch Phys Med Rehabil* 87, no. 1 (2006): 15-9.
- 546 29. Atzori, M., A. Gijsberts, C. Castellini, B. Caputo, A. G. M. Hager, S. Elsig, G. Giatsidis,  
547 F. Bassetto, and H. Muller. "Electromyography Data for Non-Invasive Naturally-  
548 Controlled Robotic Hand Prostheses." *Scientific Data* 1 (2014).

- 549 30. Lu, Z., K. Y. Tong, X. Zhang, S. Li, and P. Zhou. "Myoelectric Pattern Recognition for  
550 Controlling a Robotic Hand: A Feasibility Study in Stroke." *IEEE Trans Biomed Eng* 66,  
551 no. 2 (2019): 365-72.
- 552 31. Ryser, F., T. Butzer, J. P. Held, O. Lambercy, and R. Gassert. "Fully Embedded  
553 Myoelectric Control for a Wearable Robotic Hand Orthosis." *IEEE Int Conf Rehabil Robot*  
554 2017 (2017): 615-21.
- 555 32. Cai, S., G. Li, X. Zhang, S. Huang, H. Zheng, K. Ma, and L. Xie. "Detecting Compensatory  
556 Movements of Stroke Survivors Using Pressure Distribution Data and Machine Learning  
557 Algorithms." *J Neuroeng Rehabil* 16, no. 1 (2019): 131.
- 558 33. Jahanmiri-Nezhad, F., X. Y. Li, P. E. Barkhaus, W. Z. Rymer, and P. Zhou. "A Clinically  
559 Applicable Approach for Detecting Spontaneous Action Potential Spikes in Amyotrophic  
560 Lateral Sclerosis with a Linear Electrode Array." *Journal of Clinical Neurophysiology* 31,  
561 no. 1 (2014): 35-40.
- 562 34. Lonini, L., A. Dai, N. Shawen, T. Simuni, C. Poon, L. Shimanovich, M. Daeschler, R.  
563 Ghaffari, J. A. Rogers, and A. Jayaraman. "Wearable Sensors for Parkinson's Disease:  
564 Which Data Are Worth Collecting for Training Symptom Detection Models." *NPJ Digit*  
565 *Med* 1 (2018): 64.
- 566 35. Dobkin, B. H., and C. Martinez. "Wearable Sensors to Monitor, Enable Feedback, and  
567 Measure Outcomes of Activity and Practice." *Curr Neurol Neurosci Rep* 18, no. 12 (2018):  
568 87.
- 569 36. Voerman, G. E., J. F. Fleuren, L. A. Kallenberg, J. S. Rietman, G. J. Snoek, and H. J.  
570 Hermens. "Patient Ratings of Spasticity During Daily Activities Are Only Marginally  
571 Associated with Long-Term Surface Electromyography." *J Neurol Neurosurg Psychiatry*  
572 80, no. 2 (2009): 175-81.
- 573 37. Yamagami, M., K. M. Peters, I. Milovanovic, I. Kuang, Z. Yang, N. Lu, and K. M. Steele.  
574 "Assessment of Dry Epidermal Electrodes for Long-Term Electromyography  
575 Measurements." *Sensors (Basel)* 18, no. 4 (2018).
- 576 38. De Luca, C. J. "The Use of Surface Electromyography in Biomechanics." *Journal of*  
577 *Applied Biomechanics* 13, no. 2 (1997): 135-63.
- 578 39. Roy, S. H., G. De Luca, M. S. Cheng, A. Johansson, L. D. Gilmore, and C. J. De Luca.  
579 "Electro-Mechanical Stability of Surface Emg Sensors." *Medical & Biological*  
580 *Engineering & Computing* 45, no. 5 (2007): 447-57.
- 581 40. Beck, T. W., T. J. Housh, J. T. Cramer, M. H. Malek, M. Mielke, R. Hendrix, and J. P.  
582 Weir. "Electrode Shift and Normalization Reduce the Innervation Zone's Influence on  
583 Emg." *Medicine and Science in Sports and Exercise* 40, no. 7 (2008): 1314-22.
- 584 41. McComas, A. J., R. E. Sica, A. R. Upton, and N. Aguilera. "Functional Changes in  
585 Motoneurons of Hemiparetic Patients." *J Neurol Neurosurg Psychiatry* 36, no. 2 (1973):  
586 183-93.
- 587 42. Sica, R. E., and O. P. Sanz. "An Electrophysiological Study of the Functional Changes in  
588 the Spinal Motoneurons of Hemiparetic Patients." *Electromyogr Clin Neurophysiol* 16,  
589 no. 5 (1976): 419-31.
- 590 43. Garmirian, LRP, JPA Dewald, and AM. Acosta. "Reduction in Voluntary Activation of  
591 Elbow and Wrist Muscles in Individuals with Chronic Hemiparetic Stroke." *bioRxiv*  
592 689364 [Preprint] (2019).



- 593 44. Solnik, S., P. DeVita, P. Rider, B. Long, and T. Hortobagyi. "Teager-Kaiser Operator  
594 Improves the Accuracy of Emg Onset Detection Independent of Signal-to-Noise Ratio."  
595 *Acta Bioeng Biomech* 10, no. 2 (2008): 65-8.
- 596 45. Solnik, S., P. Rider, K. Steinweg, P. DeVita, and T. Hortobagyi. "Teager-Kaiser Energy  
597 Operator Signal Conditioning Improves Emg Onset Detection." *Eur J Appl Physiol* 110,  
598 no. 3 (2010): 489-98.
- 599 46. Li, X., and A. Aruin. "Muscle Activity Onset Time Detection Using Teager-Kaiser Energy  
600 Operator." *Conf Proc IEEE Eng Med Biol Soc 2005* (2005): 7549-52.
- 601 47. Binder-Markey BI, Murray WM, Dewald JP. . "Effects of Altered Neural Input and  
602 Botulinum Toxin on Finger and Wrist Passive Properties in Chronic Hemiparetic Stroke."  
603 *medRxiv 19011312 [Preprint]* (2020 ).
- 604 48. Schmit, B. D., J. P. Dewald, and W. Z. Rymer. "Stretch Reflex Adaptation in Elbow  
605 Flexors During Repeated Passive Movements in Unilateral Brain-Injured Patients." *Arch*  
606 *Phys Med Rehabil* 81, no. 3 (2000): 269-78.
- 607 49. Dai, C., N. L. Suresh, A. K. Suresh, W. Z. Rymer, and X. Hu. "Altered Motor Unit  
608 Discharge Coherence in Paretic Muscles of Stroke Survivors." *Front Neurol* 8 (2017): 202.
- 609 50. Hameed, H. K., W. Z. Wan Hasan, S. Shafie, S. A. Ahmad, H. Jaafar, and L. N. Inche Mat.  
610 "Investigating the Performance of an Amplitude-Independent Algorithm for Detecting the  
611 Hand Muscle Activity of Stroke Survivors." *J Med Eng Technol* 44, no. 3 (2020): 139-48.
- 612 51. Ebisuzaki, W. "A Method to Estimate the Statistical Significance of a Correlation When  
613 the Data Are Serially Correlated." *Journal of Climate* 10, no. 9 (1997): 2147-53.
- 614 52. Flansbjer, U. B., A. M. Holmback, D. Downham, C. Patten, and J. Lexell. "Reliability of  
615 Gait Performance Tests in Men and Women with Hemiparesis after Stroke." *J Rehabil Med*  
616 37, no. 2 (2005): 75-82.
- 617 53. Knorr, S., B. Brouwer, and S. J. Garland. "Validity of the Community Balance and  
618 Mobility Scale in Community-Dwelling Persons after Stroke." *Arch Phys Med Rehabil* 91,  
619 no. 6 (2010): 890-6.
- 620 54. Esquef, P. A. A., and L. W. P. Biscainho. "An Efficient Model-Based Multirate Method  
621 for Reconstruction of Audio Signals across Long Gaps." *Ieee Transactions on Audio*  
622 *Speech and Language Processing* 14, no. 4 (2006): 1391-400.
- 623 55. Mewett, D. T., H. Nazeran, and K. J. Reynolds. "Removing Power Line Noise from  
624 Recorded Emg." *Proceedings of the 23rd Annual International Conference of the Ieee*  
625 *Engineering in Medicine and Biology Society, Vols 1-4 23* (2001): 2190-93.
- 626 56. Amma, C., T. Krings, J. Boer, and T. Schultz. "Advancing Muscle-Computer Interfaces  
627 with High-Density Electromyography." *Chi 2015: Proceedings of the 33rd Annual Chi*  
628 *Conference on Human Factors in Computing Systems* (2015): 929-38.
- 629 57. Konstantin, A., T. Yu, E. Le Carpentier, Y. Aoustin, and D. Farina. "Simulation of Motor  
630 Unit Action Potential Recordings from Intramuscular Multichannel Scanning Electrodes."  
631 *IEEE Trans Biomed Eng* 67, no. 7 (2020): 2005-14.
- 632 58. Koo, T. K., and M. Y. Li. "A Guideline of Selecting and Reporting Intraclass Correlation  
633 Coefficients for Reliability Research." *J Chiropr Med* 15, no. 2 (2016): 155-63.
- 634 59. Hiragami, S., Y. Inoue, and K. Harada. "Minimal Clinically Important Difference for the  
635 Fugl-Meyer Assessment of the Upper Extremity in Convalescent Stroke Patients with  
636 Moderate to Severe Hemiparesis." *J Phys Ther Sci* 31, no. 11 (2019): 917-21.
- 637 60. Binder-Markey, B. I., W. M. Murray, and J. P. A. Dewald. "Passive Properties of the Wrist  
638 and Fingers Following Chronic Hemiparetic Stroke: Interlimb Comparisons in Persons

- 639 with and without a Clinical Treatment History That Includes Botulinum Neurotoxin."  
640 *Front Neurol* 12 (2021): 687624.
- 641 61. Baldwin, C., G. van Kessel, A. Phillips, and K. Johnston. "Accelerometry Shows Inpatients  
642 with Acute Medical or Surgical Conditions Spend Little Time Upright and Are Highly  
643 Sedentary: Systematic Review." *Phys Ther* 97, no. 11 (2017): 1044-65.
- 644 62. Ezeugwu, V. E., and P. J. Manns. "The Feasibility and Longitudinal Effects of a Home-  
645 Based Sedentary Behavior Change Intervention after Stroke." *Arch Phys Med Rehabil* 99,  
646 no. 12 (2018): 2540-47.
- 647 63. Chang, S. H., G. E. Francisco, P. Zhou, W. Z. Rymer, and S. Li. "Spasticity, Weakness,  
648 Force Variability, and Sustained Spontaneous Motor Unit Discharges of Resting Spastic-  
649 Paretic Biceps Brachii Muscles in Chronic Stroke." *Muscle Nerve* 48, no. 1 (2013): 85-92.
- 650 64. Liu, J., D. W. Ying, W. Z. Rymer, and P. Zhou. "Robust Muscle Activity Onset Detection  
651 Using an Unsupervised Electromyogram Learning Framework." *PLoS One* 10, no. 6  
652 (2015).
- 653 65. Held, J. P. O., B. Klaassen, A. Eenhoorn, B. J. F. van Beijnum, J. H. Buurke, P. H. Veltink,  
654 and A. R. Luft. "Inertial Sensor Measurements of Upper-Limb Kinematics in Stroke  
655 Patients in Clinic and Home Environment." *Frontiers in Bioengineering and*  
656 *Biotechnology* 6 (2018).
- 657 66. Schwarz, A., M. M. C. Bhagubai, G. Wolterink, J. P. O. Held, A. R. Luft, and P. H. Veltink.  
658 "Assessment of Upper Limb Movement Impairments after Stroke Using Wearable Inertial  
659 Sensing." *Sensors (Basel)* 20, no. 17 (2020).
- 660 67. Van Meulen, F. B., B. Klaassen, J. Held, J. Reenalda, J. H. Buurke, B. J. F. Van Beijnum,  
661 A. Luft, and P. H. Veltink. "Objective Evaluation of the Quality of Movement in Daily  
662 Life after Stroke." *Frontiers in Bioengineering and Biotechnology* 3 (2016).
- 663 68. Karbasforoushan, H., J. Cohen-Adad, and J. P. A. Dewald. "Brainstem and Spinal Cord  
664 Mri Identifies Altered Sensorimotor Pathways Post-Stroke." *Nat Commun* 10, no. 1 (2019):  
665 3524.
- 666 69. McPherson, J. G., A. Chen, M. D. Ellis, J. Yao, C. J. Heckman, and J. P. A. Dewald.  
667 "Progressive Recruitment of Contralesional Cortico-Reticulospinal Pathways Drives  
668 Motor Impairment Post Stroke." *J Physiol* 596, no. 7 (2018): 1211-25.
- 669 70. Owen, M., C. Ingo, and J. P. A. Dewald. "Upper Extremity Motor Impairments and  
670 Microstructural Changes in Bulbospinal Pathways in Chronic Hemiparetic Stroke." *Front*  
671 *Neurol* 8 (2017): 257.
- 672 71. Ellis, M. D., I. Schut, and J. P. A. Dewald. "Flexion Synergy Overshadows Flexor  
673 Spasticity During Reaching in Chronic Moderate to Severe Hemiparetic Stroke." *Clin*  
674 *Neurophysiol* 128, no. 7 (2017): 1308-14.
- 675 72. Lan, Y., J. Yao, and J. P. A. Dewald. "The Impact of Shoulder Abduction Loading on  
676 Volitional Hand Opening and Grasping in Chronic Hemiparetic Stroke." *Neurorehabil*  
677 *Neural Repair* 31, no. 6 (2017): 521-29.
- 678 73. Sukal, T. M., M. D. Ellis, and J. P. Dewald. "Shoulder Abduction-Induced Reductions in  
679 Reaching Work Area Following Hemiparetic Stroke: Neuroscientific Implications." *Exp*  
680 *Brain Res* 183, no. 2 (2007): 215-23.
- 681 74. Yang, Y., N. Sinha, R. Tian, N. Gurari, J. M. Drogos, and J. P. A. Dewald. "Quantifying  
682 Altered Neural Connectivity of the Stretch Reflex in Chronic Hemiparetic Stroke." *IEEE*  
683 *Trans Neural Syst Rehabil Eng* 28, no. 6 (2020): 1436-41.

- 684 75. Bhakta, B. B., J. A. Cozens, M. A. Chamberlain, and J. M. Bamford. "Quantifying  
685 Associated Reactions in the Paretic Arm in Stroke and Their Relationship to Spasticity."  
686 *Clin Rehabil* 15, no. 2 (2001): 195-206.
- 687 76. Taub, E., G. Uswatte, V. W. Mark, and D. M. Morris. "The Learned Nonuse Phenomenon:  
688 Implications for Rehabilitation." *Eura Medicophys* 42, no. 3 (2006): 241-56.
- 689 77. Feldner, H. A., C. Papazian, K. Peters, and K. M. Steele. "'It's All Sort of Cool and  
690 Interesting...But What Do I Do with It?' A Qualitative Study of Stroke Survivors'  
691 Perceptions of Surface Electromyography." *Front Neurol* 11 (2020): 1037.  
692